Key facts
- Mantis Biotech’s last known valuation is $19.0M (Dec 2025).
- It has raised $6.8M; the latest was Accelerator/Incubator ($500K) in Jan 2026.
- Notable investors include Y Combinator, Pioneer Fund, Liquid 2 Ventures, Spot VC, Decibel Partners — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Mantis Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Mantis Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mantis Biotech
Developer of a foundational infrastructure platform designed to enable the creation of human-in-computer models. The company offers unified data ingestion, physics-based simulation, and real-world validation, enabling organizations in athletics, medical technology, and defense to build production-ready human digital twins with reliable performance and accuracy.
- Sector
- Information Technology
- HQ
- San Francisco, CA, United States
- Founded
- 2025
- Employees
- 5
- Website
- mantisbiotech.com/
- Ownership
- Privately Held (backing)
Mantis Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mantis Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mantis Biotech in its N-PORT filings yet. We sweep new filings monthly.